FDA holds meeting to determine if opioid limits should be set

The FDA has started its two-day advisory committee meeting to determine if higher doses of opioids should be limited or removed from the market.

Advertisement

During the meeting, the FDA is soliciting feedback from clinical, patient, public health and research communities to better understand current clinical use of higher-dose opioids, situations that may warrant the use of higher doses and frequency of harm associated with higher doses.  

Interested parties are asked to present data, information or views in writing or in person.

The FDA’s Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesia Drug Products Advisory Committee is holding the meeting.

More articles on opioids:
KLAS: Prescription intelligence software helps improve opioid prescribing practices
Majority of cancer surgery patients discharged without opioids with new pain management protocol, study finds
Georgia officials partner with Appriss Health to integrate PDMP into EHRs

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in GLP-1s

Advertisement

Comments are closed.